You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 713 Nanrilkefusp alfa, a high-affinity IL-15Rβγ agonist, promotes an innate and adaptive anti-tumour inflammatory environment as single agent or combined with anti-PD-1 in patients with advanced cancers

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
713 Nanrilkefusp alfa, a high-affinity IL-15Rβγ agonist, promotes an innate and adaptive anti-tumour inflammatory environment as single agent or combined with anti-PD-1 in patients with advanced cancers

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023192014
Dec 20236008
Jan 20243708
Feb 20245603
Mar 20245004
Apr 20244003
May 20244005
Jun 20245206
Jul 20245207
Aug 20242201
Sep 20245405
Oct 20244404
Nov 202468014
Dec 20243405
Jan 20252205
Feb 20252207
Mar 2025006
Apr 2025101
May 2025003
Jun 2025003
Total8460112